NDA Group, PharmApprove Announce Strategic Alliance
Two leading drug development and regulatory consultancies announced they have formed a new strategic alliance to help life science companies navigate an increasingly complex global environment.
Two leading drug development and regulatory consultancies announced they have formed a new strategic alliance to help life science companies navigate an increasingly complex global environment. PharmApprove – a strategic regulatory, and scientific communications consultancy based in the US – and NDA Group – a European-based regulatory, pharmacovigilance and Health Technology Assessment (HTA) consultancy – are collaborating to provide the life science industry with integrated global regulatory, scientific and market access communications solutions.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
